News & Updates
Filter by Specialty:
Dalpiciclib a 1L option for HR-positive, HER2-negative advanced breast cancer regardless of menopausal status
05 Jul 2023
byChristina Lau
Adding dalpiciclib to an aromatase inhibitor (AI) significantly improves progression-free survival (PFS) vs an AI alone in first-line (1L) treatment of hormone receptor (HR)–positive, HER2-negative advanced breast cancer regardless of patients’ menopausal status, a phase III trial in 42 hospitals in China has shown.
Dalpiciclib a 1L option for HR-positive, HER2-negative advanced breast cancer regardless of menopausal status
05 Jul 2023
ADHD meds emerge as preferred option for reducing self-harm risk in BPD
04 Jul 2023
byJairia Dela Cruz
For individuals with bipolar disorder (BPD), attention-deficit/hyperactive disorder (ADHD) medications help lower the risk of suicidal behaviour, according to data from a comparative effectiveness research study.
ADHD meds emerge as preferred option for reducing self-harm risk in BPD
04 Jul 2023
Mood disorders affect one in ten ICD patients
04 Jul 2023
byKanas Chan
Depression, anxiety, and post-traumatic stress disorder (PTSD) are highly prevalent in patients with an implantable cardioverter defibrillator (ICD), a meta-analysis has revealed.